[1]
|
Chifman, J., Laubenbacher, R. and Torti, S.V. (2014) A Systems Biology Approach to Iron Metabolism. Advances in Experimental Medicine and Biology, 844, 201-225. https://doi.org/10.1007/978-1-4939-2095-2_10
|
[2]
|
Silvestri, L. and Magnusson, M.K. (2021) Iron Biology: The Balance Matters. Seminars in Hematology, 58, 131. https://doi.org/10.1053/j.seminhematol.2021.07.002
|
[3]
|
Gammella, E., Recalcati, S. and Cairo, G. (2016) Dual Role of ROS as Signal and Stress Agents: Iron Tips the Balance in Favor of Toxic Effects. Oxidative Medicine and Cellular Longevity, 2016, Article ID: 8629024. https://doi.org/10.1155/2016/8629024
|
[4]
|
Mleczko-Sanecka, K. and Silvestri, L. (2021) Cell-Type-Specific Insights into Iron Regulatory Processes. Journal of Hematology, 96, 110-127. https://doi.org/10.1002/ajh.26001
|
[5]
|
Turpin, C., Meilhac, O., Bourdon, E., Canonne-Hergaux, F. and Rondeau, P. (2022) Methodologies and Tools to Shed Light on Erythrophagocytosis. Biochimie, 202, 166-179. https://doi.org/10.1016/j.biochi.2022.07.017
|
[6]
|
Yanatori, I. and Kishi, F. (2019) DMT1 and Iron Transport. Free Radical Biology and Medicine, 133, 55-63. https://doi.org/10.1016/j.freeradbiomed.2018.07.020
|
[7]
|
Jiang, L., Wang, J., Wang, K., Wang, H., Wu, Q., Yang, C., et al. (2020) RNF217 Regulates Iron Homeostasis through Its E3 Ubiquitin Ligase Activity by Modulating Ferroportin Degradation. Blood, 138, 689-705. https://doi.org/10.1182/blood.2020008986
|
[8]
|
Zhou, Z.D. and Tan, E. (2017) Iron Regulatory Protein (IRP)-Iron Responsive Element (IRE) Signaling Pathway in Human Neurodegenerative Diseases. Molecular Neurodegeneration, 12, Article No. 75. https://doi.org/10.1186/s13024-017-0218-4
|
[9]
|
Zarghamian, P., Azarkeivan, A., Arabkhazaeli, A., Mardani, A. and Shahabi, M. (2021) Hepcidin Gene Polymorphisms and Iron Overload in β-Thalassemia Major Patients Refractory to Iron Chelating Therapy. Blood, 138, 689-705. https://doi.org/10.1186/s12881-020-01011-3
|
[10]
|
Xu, Y., Alfaro-Magallanes, V.M. and Babi, J.L. (2021) Physiological and Pathophysiological Mechanisms of Hepcidin Regulation: Clinical Implications for Iron Disorders. British Journal of Haematology, 193, 882-893. https://doi.org/10.1111/bjh.17252
|
[11]
|
Praeger-Jahnsen, L., Magnussen, K., Schiødt, F.V., Therkildsen, R.C., Jørgensen, N. and Friis-Hansen, L. (2023) A Novel Hepcidin Mutation. Transfusion Clinique et Biologique, 30, 335-340. https://doi.org/10.1016/j.tracli.2023.03.001
|
[12]
|
Hennigar, S.R., Berryman, C.E., Harris, M.N., Karl, J.P., Lieberman, H.R., McClung, J.P., et al. (2020) Testosterone Administration during Energy Deficit Suppresses Hepcidin and Increases Iron Availability for Erythropoiesis. The Journal of Clinical Endocrinology & Metabolism, 105, e1316-e1321. https://doi.org/10.1210/clinem/dgz316
|
[13]
|
Silvestri, L., Nai, A., Dulja, A. and Pagani, A. (2019) Hepcidin and the BMP-SMAD Pathway: An Unexpected Liaison. Vitamins and Hormones, 110, 71-99. https://doi.org/10.1016/bs.vh.2019.01.004
|
[14]
|
Vasco, M., Signoriello, G., Scognamiglio, M., Moccia, G., Filauri, P., Sansone, A., et al. (2023) Reduced Levels of Hepcidin Associated with Lower Ferritin Concentration and Increased Number of Previous Donations in Periodic Blood Donors: A Pilot Study. Transfusion Clinique et Biologique, 30, 319-323. https://doi.org/10.1016/j.tracli.2023.04.002
|
[15]
|
Camaschella, C. (2009) BMP6 Orchestrates Iron Metabolism. Nature Genetics, 41, 386-388. https://doi.org/10.1038/ng0409-386
|
[16]
|
Meynard, D., Vaja, V., Sun, CC., Corradini, E., Chen, S., López-Otín, C., et al. (2011) Regulation of TMPRSS6 by BMP6 and Iron in Human Cells and Mice. Blood, 118, 747-756. https://doi.org/10.1182/blood-2011-04-348698
|
[17]
|
Core, A.B., Canali, S. and Babitt, J.L. (2014) Hemojuvelin and Bone Morphogenetic Protein (BMP) Signaling in Iron Homeostasis. Frontiers in Pharmacology, 5, Article 104. https://doi.org/10.3389/fphar.2014.00104
|
[18]
|
Arezes, J., Foy, N., McHugh, K., Sawant, A., Quinkert, D., Terraube, V., et al. (2018) Erythroferrone Inhibits the Induction of Hepcidin by BMP6. Blood, 132, 1473-1477. https://doi.org/10.1182/blood-2018-06-857995
|
[19]
|
Dion, S.P., Désilets, A., Lemieux, G. and Leduc, R. (2022) Functionally Impaired Isoforms Regulate TMPRSS6 Proteolytic Activity. PLOS ONE, 17, e0273825. https://doi.org/10.1371/journal.pone.0273825
|
[20]
|
Jallow, M.W., Campino, S., Prentice, A.M. and Cerami, C. (2021) Association of Common TMPRSS6 and TF Gene Variants with Hepcidin and Iron Status in Healthy Rural Gambians. Scientific Reports, 11, Article No. 8075. https://doi.org/10.1038/s41598-021-87565-5
|
[21]
|
Béliveau, F., Tarkar, A., Dion, S.P., Désilets, A., Ghinet, M.G., Boudreault, P.L., et al. (2019) Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes. Cell Chemical Biology, 26, 1559-1572. https://doi.org/10.1016/j.chembiol.2019.09.004
|
[22]
|
Batar, B., Bavunoglu, I., Hacioglu, Y., Cengiz, M., Mutlu, T., Yavuzer, S., et al. (2018) The Role of TMPRSS6 Gene Variants in Iron-Related Hematological Parameters in Turkish Patients with Iron Deficiency Anemia. Gene, 673, 201-205. https://doi.org/10.1016/j.gene.2018.06.055
|
[23]
|
Pagani, A., Nai, A., Silvestri, L. and Camaschella, C. (2019) Hepcidin and Anemia: A Tight Relationship. Frontiers in Physiology, 10, Article 1294. https://doi.org/10.3389/fphys.2019.01294
|
[24]
|
Saad, H.K.M., Abd Rahman, A.A., Ab Ghani, A.S., Taib, W.R.W., Ismail, I., Johan, M.F., et al. (2022) Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients. Biomedicines, 10, Article 189. https://doi.org/10.3390/biomedicines10010189
|
[25]
|
Billesbølle, C.B., Azumaya, C.M., Kretsch, R.C., Powers, A.S., Gonen, S., Schneider, S., et al. (2020) Structure of Hepcidin-Bound Ferroportin Reveals Iron Homeostatic Mechanisms. Nature, 586, 807-811. https://doi.org/10.1038/s41586-020-2668-z
|
[26]
|
Wierzbicka, D. and Gromadzka, G. (2014) Ceruloplasmin, Hephaestin and Zyklopen: The Three Multicopper Oxidases Important for Human Iron Metabolism. Postepy Higieny i Medycyny Doswiadczalnej, 68, 912-924. https://doi.org/10.5604/17322693.1111136
|
[27]
|
Corradini, E., Buzzetti, E., Dongiovanni, P., Scarlini, S., Caleffi, A., Pelusi, S., et al. (2021) Ceruloplasmin Gene Variants Are Associated with Hyperferritinemia and Increased Liver Iron in Patients with NAFLD. Journal of Hepatology, 75, 506-513. https://doi.org/10.1016/j.jhep.2021.03.014
|
[28]
|
Ward, D.M. and Kaplan, J. (2012) Ferroportin-Mediated Iron Transport: Expression and Regulation. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1823, 1426-1433. https://doi.org/10.1016/j.bbamcr.2012.03.004
|
[29]
|
Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., et al. (2004) Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science, 306, 2090-2093. https://doi.org/10.1126/science.1104742
|
[30]
|
Eisenstein, R.S. (2000) Discovery of the Ceruloplasmin Homologue Hephaestin: New Insight into the Copper/Iron Connection. Nutrition Reviews, 58, 22-26. https://doi.org/10.1111/j.1753-4887.2000.tb01821.x
|
[31]
|
Angmo, S., Tripathi, N., Abbat, S., Sharma, S., Sardul, Singh, S., Halder, A., et al. (2017) Identification of Guanosine 5’-Diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/ Stat-3 Pathway. Scientific Reports, 7, Article No. 40097. https://doi.org/10.1038/srep40097
|
[32]
|
Srole, D.N. and Ganz, T. (2021) Erythroferrone Structure, Function, and Physiology: Iron Homeostasis and Beyond. Journal of Cellular Physiology, 236, 4888-4901. https://doi.org/10.1002/jcp.30247
|
[33]
|
Mast, J.F., Leach, E.A. and Thompson, T.B. (2024) Characterization of Erythroferrone Oligomerization and Its Impact on BMP Antagonism. Journal of Biological Chemistry, 300, Article 105452. https://doi.org/10.1016/j.jbc.2023.105452
|
[34]
|
Babitt, J.L. (2022) Erythroferrone in Iron Regulation and Beyond. Blood, 139, 319-321. https://doi.org/10.1182/blood.2021014326
|
[35]
|
Asperti, M., Denardo, A., Gryzik, M., Arosio, P. and Poli, M. (2019) The Role of Heparin, Heparanase and Heparan Sulfates in Hepcidin Regulation. Vitamins and Hormones, 110, 157-188. https://doi.org/10.1016/bs.vh.2019.01.008
|
[36]
|
Vagionas, D., Politou, M., Kompoti, M., Papadakis, D.D., Kostakou, E., Theodoulou, D., et al. (2021) Unfractionated Heparin Reduces Hepcidin Levels in Critically Ill Patients. Internal Medicine Journal, 51, 797-801. https://doi.org/10.1111/imj.15317
|
[37]
|
Colucci, S., Pagani, A., Pettinato, M., Artuso, I., Nai, A., Camaschella, C. and Silvestri, L. (2017) The Immunophilin FKBP12 Inhibits Hepcidin Expression by Binding the BMP Type I Receptor ALK2 in Hepatocytes. Blood, 130, 2111-2120. https://doi.org/10.1182/blood-2017-04-780692
|
[38]
|
Fang, X., Ardehali, H., Min, J. and Wang, F. (2023) The Molecular and Metabolic Landscape of Iron and Ferroptosis in Cardiovascular Disease. Nature Reviews Cardiology, 20, 7-23. https://doi.org/10.1038/s41569-022-00735-4
|
[39]
|
Vela, D. (2018) Balance of Cardiac and Systemic Hepcidin and Its Role in Heart Physiology and Pathology. Laboratory Investigation, 98, 315-326. https://doi.org/10.1038/labinvest.2017.111
|
[40]
|
Lakhal-Littleton, S. (2019) Cardiomyocyte Hepcidin: From Intracellular Iron Homeostasis to Physiological Function. Vitamins and Hormones, 110, 189-200. https://doi.org/10.1016/bs.vh.2019.01.009
|
[41]
|
Merle, U., Fein, E., Gehrke, S.G., Stremmel, W. and Kulaksiz, H. (2007) The Iron Regulatory Peptide Hepcidin Is Expressed in the Heart and Regulated by Hypoxia and Inflammation. Endocrinology, 148, 2663-2668. https://doi.org/10.1210/en.2006-1331
|
[42]
|
Berezovsky, B., Frýdlová, J., Gurieva, I., Rogalsky, D.W., Vokurka, M. and Krijt, J. (2022) Heart Ferroportin Protein Content Is Regulated by Heart Iron Concentration and Systemic Hepcidin Expression. International Journal of Molecular Sciences, 23, Article 5899. https://doi.org/10.3390/ijms23115899
|
[43]
|
Jayakumar, D., Narasimhan, K.K. and Periandavan, K. (2022) Triad Role of Hepcidin, Ferroportin, and Nrf2 in Cardiac Iron Metabolism: From Health to Disease. Journal of Trace Elements in Medicine and Biology, 69, Article 126882. https://doi.org/10.1016/j.jtemb.2021.126882
|
[44]
|
Sasai, M., Iso, Y., Mizukami, T., Tomosugi, N., Sambe, T., Miyazaki, A. and Suzuki, H. (2017) Potential Contribution of the Hepcidin-Macrophage Axis to Plaque Vulnerability in Acute Myocardial Infarction in Human. Journal of Cardiology, 227, 114-121. https://doi.org/10.1016/j.ijcard.2016.11.147
|
[45]
|
Zlatanova, I., Pinto, C., Bonnin, P., Mathieu, J.R.R., Bakker, W., Vilar, J., et al. (2019) Iron Regulator Hepcidin Impairs Macrophage-Dependent Cardiac Repair after Injury. Circulation, 139, 1530-1547. https://doi.org/10.1161/CIRCULATIONAHA.118.034545
|
[46]
|
Kobak, K.A., Radwańska, M., Dzięgała, M., Kasztura, M., Josiak, K., Banasiak, W., et al. (2019) Structural and Functional Abnormalities in Iron-Depleted Heart. Heart Failure Reviews, 24, 269-277. https://doi.org/10.1007/s10741-018-9738-4
|
[47]
|
Manolov, V., Petrova, J., Bogov, B., Hadjidekova, S., Vasilev, V., Yonova, D., et al. (2017) Evaluation of Hepcidin and Atherosclerosis in Dialysis Patients. Clinical Laboratory, 63, 1787-1792. https://doi.org/10.7754/Clin.Lab.2017.170336
|
[48]
|
Golfeyz, S., Lewis, S. and Weisberg, I.S. (2018) Hemochromatosis: Pathophysiology, Evaluation, and Management of Hepatic Iron Overload with a Focus on MRI. Expert Review of Gastroenterology & Hepatology, 12, 767-778. https://doi.org/10.1080/17474124.2018.1496016
|
[49]
|
Huang, Y.H. and Kuo, H.C. (2017) Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker. International Journal of Molecular Sciences, 18, Article 820. https://doi.org/10.3390/ijms18040820
|
[50]
|
Suárez-Ortegón, M.F., Arbeláez, A., Mosquera, M., Moreno-Navarrete, J.M., Aguilar-Plata, C. and Fernández-Real, J.M. (2015) Circulating Hepcidin Is Independently Associated with Systolic Blood Pressure in Apparently Healthy Individuals. Archives of Medical Research, 46, 507-513. https://doi.org/10.1016/j.arcmed.2015.07.007
|
[51]
|
Loncar, G., Obradovic, D., Thiele, H., Von Haehling, S. and Lainscak, M. (2021) Iron Deficiency in Heart Failure. ESC Heart Failure Journal, 8, 2368-2379. https://doi.org/10.1002/ehf2.13265
|
[52]
|
Anand, I.S. and Gupta, P. (2018) Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation, 138, 80-98. https://doi.org/10.1161/CIRCULATIONAHA.118.030099
|
[53]
|
Chopra, V.K. and Anker, S.D. (2020) Anaemia, Iron Deficiency and Heart Failure in 2020: Facts and Numbers. ESC Heart Failure Journal, 7, 2007-2011. https://doi.org/10.1002/ehf2.12797
|
[54]
|
Alnuwaysir, R.I.S., Hoes, M.F., Van Veldhuisen, D.J., Van der Meer, P. and Grote Beverborg, N. (2021) Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. Journal of Clinical Medicine, 11, Article 125. https://doi.org/10.3390/jcm11010125
|
[55]
|
Kozłowska, B., Sochanowicz, B., Kraj, L., Palusińska, M., Kołsut, P., Szymański, L., et al. (2022) Expression of Iron Metabolism Proteins in Patients with Chronic Heart Failure. Journal of Clinical Medicine, 11, Article 837. https://doi.org/10.3390/jcm11030837
|
[56]
|
Zhang, H., Lockhart, Jamieson, K., Grenier, J., Nikhanj, A., Tang, Z., Wang, F., et al. (2022) Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans. Journal of the American Heart Association, 11, e022853. https://doi.org/10.1161/JAHA.121.022853
|
[57]
|
Hanna, A. and Frangogiannis, N.G. (2020) Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovascular Drugs and Therapy, 34, 849-863. https://doi.org/10.1007/s10557-020-07071-0
|
[58]
|
Remmelzwaal, S., Van Oort, S., Handoko, M.L., Van Empel, V., Heymans, S.R.B. and Beulens, J.W.J. (2022) Inflammation and Heart Failure: A Two-Sample Mendelian Randomization Study. Journal of Cardiovascular Medicine (Hagerstown), 23, 728-735. https://doi.org/10.2459/JCM.0000000000001373
|
[59]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., Allen, L.A., Byun, J.J., Colvin, M.M., et al. (2022) AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e895-e1032. https://doi.org/10.1161/CIR.0000000000001073
|
[60]
|
Manceau, H., Ausseil, J., Masson, D., Feugeas, J.P., Sablonniere, B., Guieu, R., et al. (2022) Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency. Nutrients, 14, Article 3214. https://doi.org/10.3390/nu14153214
|
[61]
|
Rizzo, C., Carbonara, R., Ruggieri, R., Passantino, A. and Scrutinio, D. (2021) Iron Deficiency: A New Target for Patients with Heart Failure. Frontiers in Cardiovascular Medicine, 8, Article 709872. https://doi.org/10.3389/fcvm.2021.709872
|
[62]
|
Reissig Pereira, G.A. and Beck-da-Silva, L. (2022) Iron Deficiency in Heart Failure with Reduced Ejection Fraction: Pathophysiology, Diagnosis and Treatment. Arquivos Brasileiros de Cardiologia, 118, 646-654. https://doi.org/10.36660/abc.20201257
|
[63]
|
Halade, G.V. and Lee, D.H. (2022) Inflammation and Resolution Signaling in Cardiac Repair and Heart Failure. eBioMedicine, 79, Article 103992. https://doi.org/10.1016/j.ebiom.2022.103992
|
[64]
|
Adamo, L., Rocha-Resende, C., Prabhu, S.D. and Mann, D.L. (2020) Reappraising the Role of Inflammation in Heart Failure. Nature Reviews Cardiology, 17, 269-285. https://doi.org/10.1038/s41569-019-0315-x
|
[65]
|
Triposkiadis, F., Xanthopoulos, A., Starling, R.C. and Iliodromitis, E. (2022) Obesity, Inflammation, and Heart Failure: Links and Misconceptions. Heart Failure Reviews, 27, 407-418. https://doi.org/10.1007/s10741-021-10103-y
|
[66]
|
Jankowska, E.A., Kirwan, B.A., Kosiborod, M., Butler, J., Anker, S.D., McDonagh, T., et al. (2021) The Effect of Intravenous Ferric Carboxymaltose on Health-Related Quality of Life in Iron-Deficient Patients with Acute Heart Failure: The Results of the AFFIRM-AHF Study. European Heart Journal, 42, 3011-3020. https://doi.org/10.1093/eurheartj/ehab234
|
[67]
|
Alnuwaysir, R.I.S., Beverborg, N.G., Hoes, M., Markousis-Mavrogenis, G., Gomez, K.A., Van der Wal, H.H., et al. (2022) Additional Burden of Iron Deficiency in Heart Failure Patients Beyond the Cardio-Renal Anaemia Syndrome: Findings from the BIOSTAT-CHF Study. European Journal of Heart Failure, 24, 192-204. https://doi.org/10.1002/ejhf.2393
|
[68]
|
Khatami, F., Muka, T., Groothof, D., De Borst, M.H., Chepkoech, B., Van Hassel, G., et al. (2022) Sex and N-Terminal Pro B-Type Natriuretic Peptide: The Potential Mediating Role of Iron Biomarkers. Frontiers in Cardiovascular Medicine, 9, Article 897148. https://doi.org/10.3389/fcvm.2022.897148
|
[69]
|
Afsar, R.E., Kanbay, M., Ibis, A. and Afsar, B. (2021) In-Depth Review: Is Hepcidin a Marker for the Heart and the Kidney? Molecular and Cellular Biochemistry, 476, 3365-3381. https://doi.org/10.1007/s11010-021-04168-4
|
[70]
|
Koeppen, A.H., Ramirez, R.L., Becker, A.B., Bjork, S.T., Levi, S., Santambrogio, P., et al. (2015) The Pathogenesis of Cardiomyopathy in Friedreich Ataxia. PLOS ONE, 10, e0116396. https://doi.org/10.1371/journal.pone.0116396
|
[71]
|
Paterek, A., Mackiewicz, U. and Mączewski, M. (2019) Iron and the Heart: A Paradigm Shift from Systemic to Cardiomyocyte Abnormalities. Journal of Cellular Physiology, 234, 21613-21629. https://doi.org/10.1002/jcp.28820
|
[72]
|
Galaris, D., Barbouti, A. and Pantopoulos, K. (2019) Iron Homeostasis and Oxidative Stress: An Intimate Relationship. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1866, Article 118535. https://doi.org/10.1016/j.bbamcr.2019.118535
|
[73]
|
Knutson, M.D. (2019) Non-Transferrin-Bound Iron Transporters. Free Radical Biology and Medicine, 133, 101-111. https://doi.org/10.1016/j.freeradbiomed.2018.10.413
|
[74]
|
Limbu, S., Hoang-Trong, T.M., Prosser, B.L., Lederer, W.J. and Jafri, M.S. (2015) Modeling Local X-ROS and Calcium Signaling in the Heart. Biophysical Journal, 109, 2037-2050. https://doi.org/10.1016/j.bpj.2015.09.031
|
[75]
|
Takano, H., Zou, Y., Hiroshi, H., Hiroshi, A., Nagai, T. and Komuro, I. (2003) Oxidative Stress-Induced Signal Transduction Pathways in Cardiac Myocytes: Involvement of ROS in Heart Diseases. Antioxidants and Redox Signaling, 5, 789-794. https://doi.org/10.1089/152308603770380098
|
[76]
|
Bayraktar, A., Erbaş, D., Dizakar Saadet, Ö.A., Göktaş, T., Ömeroğlu, S. and Öz Oyar, E. (2020) The Effect of Hepcidin on Cardiac Ischemia-Reperfusion Injury. Journal of Investigative Surgery, 33, 813-821. https://doi.org/10.1080/08941939.2019.1579275
|
[77]
|
Zhao, K., Chen, X., Bian, Y., Zhou, Z., Wei, X. and Zhang, J. (2023) Broadening Horizons: The Role of Ferroptosis in Myocardial Ischemia-Reperfusion Injury. Naunyn- Schmiedeberg’s Archives of Pharmacology, 396, 2269-2286. https://doi.org/10.1007/s00210-023-02506-5
|
[78]
|
Li, N., Jiang, W., Wang, W., Xiong, R., Wu, X. and Geng, Q. (2021) Ferroptosis and Its Emerging Roles in Cardiovascular Diseases. Pharmacological Research, 166, Article 105466. https://doi.org/10.1016/j.phrs.2021.105466
|
[79]
|
Nakamura, T., Naguro, I. and Ichijo, H. (2019) Iron Homeostasis and Iron-Regulated ROS in Cell Death, Senescence and Human Diseases. Biochimica et Biophysica Acta (BBA)—General Subjects, 1863, 1398-1409. https://doi.org/10.1016/j.bbagen.2019.06.010
|
[80]
|
Zhang, K., Tian, X.-M., Li, W. and Hao, L.Y. (2023) Ferroptosis in Cardiac Hypertrophy and Heart Failure. Biomedicine & Pharmacotherapy, 168, Article 115765. https://doi.org/10.1016/j.biopha.2023.115765
|
[81]
|
Suzuki, H., Toba, K., Kato, K., Ozawa, T., Tomosugi, N., Higuchi, M., et al. (2009) Serum Hepcidin-20 Is Elevated during the Acute Phase of Myocardial Infarction. Tohoku Journal of Experimental Medicine, 218, 93-98. https://doi.org/10.1620/tjem.218.93
|
[82]
|
Sullivan, J.L. (2007) Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability. Experimental Biology and Medicine (Maywood), 232, 1014-1020. https://doi.org/10.3181/0703-MR-54
|
[83]
|
Chaudhary, S., Ashok, A., Wise, A.S., Rana, N.A., McDonald, D., Kritikos, A.E., et al. (2021) Upregulation of Brain Hepcidin in Prion Diseases. Prion, 15, 126-137. https://doi.org/10.1080/19336896.2021.1946377
|
[84]
|
Bowers, K. and Srai, S.K.S. (2018) The Trafficking of Metal Ion Transporters of the Zrt-and Irt-Like Protein Family. Traffic, 19, 813-822. https://doi.org/10.1111/tra.12602
|
[85]
|
Cacoub, P., Choukroun, G., Cohen-Solal, A., Luporsi, E., Peyrin-Biroulet, L., Peoc’h, K., et al. (2022) Iron Deficiency Screening Is a Key Issue in Chronic Inflammatory Diseases: A Call to Action. Journal of Internal Medicine, 292, 542-556. https://doi.org/10.1111/joim.13503
|
[86]
|
Al-Amer, O. and Alsharif, K.F. (2021) Frequency of the HAMP (c.-582 A>G) Polymorphism in Iron Deficiency in Saudi Arabia. Pakistan Journal of Biological Sciences, 24, 146-150. https://doi.org/10.3923/pjbs.2021.146.150
|
[87]
|
Fonseca, P.F.S., Delfini Cançado, R., Uellendahl Lopes, M.M., Correia, E., Lescano, M.A. and Caleb Junior Lima Santos, P. (2016) HAMP Gene Mutation Associated with Juvenile Hemochromatosis in Brazilian Patients. Acta Haematologica, 135, 228-231. https://doi.org/10.1159/000444119
|
[88]
|
Hernández, G., Ferrer-Cortès, X., Venturi, V., Musri, M., Pilquil, M.F., Muñoz Torres, M., et al. (2021) New Mutations in HFE2 and TFR2 Genes Causing Non HFE-Related Hereditary Hemochromatosis. Genes, 12, Article 1980. https://doi.org/10.3390/genes12121980
|
[89]
|
Wang, W., Du, Y., Liu, G., Guo, S., Hou, B., Jiang, X., et al. (2017) Identification of Novel Mutations in HFE, HFE2, TfR2, and SLC40A1 Genes in Chinese Patients Affected by Hereditary Hemochromatosis. Journal of Hematology, 105, 521-525. https://doi.org/10.1007/s12185-016-2150-8
|
[90]
|
Calado, R.T., Franco, R.F., Pazin-Filho, A., Simões, M.V., Marin-Neto, J.A. and Zago, M.A. (2000) HFE Gene Mutations in Coronary Atherothrombotic Disease. Brazilian Journal of Medical and Biological Research, 33, 301-306. https://doi.org/10.1590/S0100-879X2000000300007
|
[91]
|
Aslan, D., Crain, K. and Beutler, E. (2007) A New Case of Human Atransferrinemia with a Previously Undescribed Mutation in the Transferrin Gene. Acta Haematologica, 118, 244-247. https://doi.org/10.1159/000112726
|
[92]
|
Lazar-Poloczek, E., Romuk, E., Rozentryt, P., Duda, S., Gąsior, M. and Wojciechowska, C. (2021) Ceruloplasmin as Redox Marker Related to Heart Failure Severity. International Journal of Molecular Sciences, 22, Article 10074. https://doi.org/10.3390/ijms221810074
|
[93]
|
Wilbon, A.S., Shen, J., Ruchala, P., Zhou, M. and Pan, Y. (2023) Structural Basis of Ferroportin Inhibition by Minihepcidin PR73. PLOS Biology, 21, e3001936. https://doi.org/10.1371/journal.pbio.3001936
|
[94]
|
Langer, A.L. and Esrick, E.B. (2021) β-Thalassemia: Evolving Treatment Options beyond Transfusion and Iron Chelation. Hematology, ASH Education Program, 2021, 600-606. https://doi.org/10.1182/hematology.2021000313
|
[95]
|
Kowdley, K.V., Modi, N.B., Peltekian, K., Vierling, J.M., Ferris, C., Valone, F.H. and Gupta, S. (2023) Rusfertide for the Treatment of Iron Overload in HFE-Related Haemochromatosis: An Open-Label, Multicentre, Proof-of-Concept Phase 2 Trial. The Lancet Gastroenterology and Hepatology, 8, 1118-1128. https://doi.org/10.1016/S2468-1253(23)00250-9
|
[96]
|
Renders, L., Budde, K., Rosenberger, C., Van Swelm, R., Swinkels, D., Dellanna, F., et al. (2019) First-in-Human Phase I Studies of PRS-080#22, a Hepcidin Antagonist, in Healthy Volunteers and Patients with Chronic Kidney Disease Undergoing Hemodialysis. PLOS ONE, 14, e0212023. https://doi.org/10.1371/journal.pone.0212023
|
[97]
|
Packer, M. (2022) How Can Sodium-Glucose Cotransporter 2 Inhibitors Stimulate Erythrocytosis in Patients Who Are Iron-Deficient? Implications for Understanding Iron Homeostasis in Heart Failure. European Journal of Heart Failure, 24, 2287-2296. https://doi.org/10.1002/ejhf.2731
|
[98]
|
Packer, M. (2023) Mechanisms of Enhanced Renal and Hepatic Erythropoietin Synthesis by Sodium-Glucose Cotransporter 2 Inhibitors. European Heart Journal, 44, 5027-5035. https://doi.org/10.1093/eurheartj/ehad235
|
[99]
|
Gronda, E., Lopaschuk, G.D., Arduini, A., Santoro, A., Benincasa, G., Palazzuoli, A., et al. (2022) Mechanisms of Action of SGLT2 Inhibitors and Their Beneficial Effects on the Cardiorenal Axis. Canadian Journal of Physiology and Pharmacology, 100, 93-106. https://doi.org/10.1139/cjpp-2021-0399
|
[100]
|
Ganz, T., Nemeth, E., Rivella, S., Goldberg, P., Dibble, A.R., McCaleb, M.L., et al. (2023) TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis. Advances in Therapy, 40, 1317-1333. https://doi.org/10.1007/s12325-022-02421-w
|
[101]
|
Duca, L., Granata, F., Di Pierro, E., Brancaleoni, V., Graziadei, G. and Nava, I. (2022) Associated Effect of SLC40A1 and TMPRSS6 Polymorphisms on Iron Overload. Metabolities, 12, Article 919. https://doi.org/10.3390/metabo12100919
|
[102]
|
Torti, S.V., Lemler, E., Mueller, B.K., Popp, A. and Torti, F.M. (2016) Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts. Clinical and Experimental Pharmacology, 6, 223.
|
[103]
|
Wang, L., Trebicka, E., Fu, Y., Ellenbogen, S., Hong, C.C., Babitt, J.L., et al. (2012) The Bone Morphogenetic Protein-Hepcidin Axis as a Therapeutic Target in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 18, 112-119. https://doi.org/10.1002/ibd.21675
|
[104]
|
Cavallaro, F., Duca, L., Pisani, L.F., Rigolini, R., Spina, L., Tontini, G.E., et al. (2017) Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Canadian Journal of Gastroenterology and Hepatology, 2017, Article ID: 6843976. https://doi.org/10.1155/2017/6843976
|
[105]
|
Pergola, P.E., Devalaraja, M., Fishbane, S., Chonchol, M., Mathur, V.S., Smith, M.T., et al. (2021) Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Society of Nephrology, 32, 211-222. https://doi.org/10.1681/ASN.2020050595
|
[106]
|
Lehmann, E.F., Liziczai, M., Drożdżyk, K., Altermatt, P., Langini, C., Manolova, V., et al. (2023) Structures of Ferroportin in Complex with Its Specific Inhibitor Vamifeport. eLife, 12, e83053. https://doi.org/10.7554/eLife.83053
|
[107]
|
Richard, F., Van Lier, J.J., Roubert, B., Haboubi, T., Göhring, U.M. and Dürrenberger, F. (2020) Oral Ferroportin Inhibitor VIT-2763: First-in-Human, Phase 1 Study in Healthy Volunteers. American Journal of Hematology, 95, 68-77. https://doi.org/10.1002/ajh.25670
|
[108]
|
Nalado, A.M., Olorunfemi, G., Dix-Peek, T., Dickens, C., Khambule, L., Snyman, T., et al. (2020) Hepcidin and GDF-15 Are Potential Biomarkers of Iron Deficiency Anaemia in Chronic Kidney Disease Patients in South Africa. BMC Nephrology, 21, Article No. 415. https://doi.org/10.1186/s12882-020-02046-7
|
[109]
|
Mleczko-Sanecka, K., Da Silva, A.R., Call, D., Neves, J., Schmeer, N., Damm, G., et al. (2017) Imatinib and Spironolactone Suppress Hepcidin Expression. Haematologica, 102, 1173-1184. https://doi.org/10.3324/haematol.2016.162917
|
[110]
|
Poli, M., Asperti, M., Ruzzenenti, P., Naggi, A. and Arosio, P. (2017) Non-Anticoagulant Heparins Are Hepcidin Antagonists for the Treatment of Anemia. Molecules, 22, Article 598. https://doi.org/10.3390/molecules22040598
|
[111]
|
Aschemeyer, S., Gabayan, V., Ganz, T., Nemeth, E. and Kautz, L. (2017) Erythroferrone and Matriptase-2 Independently Regulate Hepcidin Expression A. Journal of Hematology, 92, e61-e63. https://doi.org/10.1002/ajh.24672
|